The shortage of drugs from CVI was explained in "SK-Pharmacy"

In "SK-Pharmacy" they answered to Orda.kz that due to the difficult epidemiological situation, the need for the drug "Tocilizumab", which is used for the treatment of seriously ill with COVID-19, has increased two times and a shortage has been created, and the company is currently working on reducing it.

Before we received the answer, the deputy of the Mazhilis Azat Peruashev appealed to the Minister of Healthcare Alexey Tsoy with a request to deal with the shortage of anti-covid drugs in hospitals. Citizens in social networks began to point out that an acute shortage of drugs "Remdesivir" and "Tocilizumab" (Actemra), used for seriously ill patients with coronavirus infection, has already begun in infectious hospitals.

The press-service of "SK-Pharmacy" explained that the purchase of the drug is carried out in the volume formed by medical organizations and is delivered in accordance with the established schedule. Additional purchase of medicines is carried out based on the analysis of consumption by medical organizations and monitoring of balance in the warehouses of the company and medical institutions.

— Due to the epidemiological situation, the growth of drug consumption increased by 2 times, — the press service said.

"SK-Pharmacy" notes that the drug "Tocilizumab" is not included in the formed 2-month non-reduced stock of drugs for the treatment of COVID-19.

Medical organizations, taking into account the additional volume, announced the need for 7,043 vials by the end of the year. "SK-Pharmacy" reports that it has already delivered 4,517 vials to the medical organization. August 2, 771 vials were shipped ahead of schedule. It is also planned to ship 1113 vials ahead of schedule.

To meet the additional needs from medical organizations, the Single distributor stated that he had worked out the issue of additional supply of "Aktemra" 80mg in the amount of 1277 vials in two dosages. The purchase contract with the supplier of additional volume is at the stage of signing.

According to the organization, the demand for this drug has increased worldwide due to the increase in morbidity of COVID-19.

The press service of the SD also commented the state of the non-reduced stock of medicines from COVID-19.

— The Ministry of Healthcare approved 38 positions of medicines of an non-reduced stock for the treatment of COVID-19 in the amount of 6.4 billion tenge. The volume of these positions will allow to cover 60 thousand patients per month with treatment. The volume of a two-month stock of medicines for COVID-19 is distributed and stored at the hubs of the Single distributor upon the consumption of medicines by regions in 2020: Almaty – 35%, Nur-Sultan - 30%, Aktobe – 15%, Shymkent – 20%.

Information about the shortage of the drug "Tocilizumab" appeared in the editorial office on July 31.